Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
T126856-250mg | 250mg | In stock | $45.90 | |
T126856-1g | 1g | In stock | $140.90 | |
T126856-5g | 5g | In stock | $351.90 | |
T126856-25g | 25g | In stock | $1,581.90 | |
T126856-100g | 100g | In stock | $5,694.90 |
Immunomodulator and anticancer agent
Synonyms | thalidomide|50-35-1|Thalomid|2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione|Contergan|Distaval|Pantosediv|Softenon|(+/-)-THALIDOMIDE|Kevadon|Sedoval|Theophilcholine|Algosediv|Corronarobetin|Ectiluran|Enterosediv|Gastrinide|Nerosedyn|Neurosedin|Neurosedy |
---|---|
Specifications & Purity | ≥98% |
Shipped In | Normal |
Action Type | INHIBITOR |
Mechanism of action | CRL4(CRBN) E3 ubiquitin ligase inhibitor |
Product Description | A selective inhibitor of TNF alpha biosynthesis shown to have immunomodulatory and antiangeogenic activity. |
ALogP | 0.3 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
---|---|
INCHI | InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17) |
InChi Key | UEJJHQNACJXSKW-UHFFFAOYSA-N |
Canonical SMILES | C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O |
Isomeric SMILES | C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O |
WGK Germany | 3 |
RTECS | TI4375000 |
PubChem CID | 5426 |
UN Number | 2811 |
Packing Group | I |
Molecular Weight | 258.23 |
DrugBank Ligand | DB01041 |
---|---|
PubChem CID | 5426 |
CAS Registry No. | 50-35-1 |
ChEMBL Ligand | CHEMBL468 |
Wikipedia | Thalidomide |
Immunopaedia Search | thalidomide |
Reactome Reaction | R-HSA-9681169 |
Reactome Drug | R-ALL-9681254 |
DrugCentral Ligand | 2616 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
J2213865 | Certificate of Analysis | Jul 08, 2024 | T126856 |
J2214041 | Certificate of Analysis | Jul 08, 2024 | T126856 |
J2214177 | Certificate of Analysis | Jul 08, 2024 | T126856 |
J2214182 | Certificate of Analysis | Jul 08, 2024 | T126856 |
J2214183 | Certificate of Analysis | Jul 08, 2024 | T126856 |
I1506144 | Certificate of Analysis | Mar 16, 2023 | T126856 |
H2026219 | Certificate of Analysis | Jul 11, 2022 | T126856 |
H2019013 | Certificate of Analysis | Jun 20, 2022 | T126856 |
Solubility | Soluble in DMSO (>25 mg/ml), cold pyridine, dimethylformamide, dioxane, Acetone, Butyl Acetate, Ethanol (≥2 mg/ml), Ethyl Acetate, Methanol, water (<1 mg/mL ), and 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin (0.6 mg/mL). |
---|---|
Melt Point(°C) | 276 °C |
Pictogram(s) | GHS08, GHS07 |
---|---|
Signal | Danger |
Hazard Statements | H302:Harmful if swallowed H360:May damage fertility or the unborn child |
Precautionary Statements | P280:Wear protective gloves/protective clothing/eye protection/face protection. P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P270:Do not eat, drink or smoke when using this product. P330:Rinse mouth. P203:Obtain, read and follow all safety instructions before use. P301+P317:IF SWALLOWED: Get medical help. P318:if exposed or concerned, get medical advice. |
WGK Germany | 3 |
RTECS | TI4375000 |
Class | 6.1 |
Merck Index | 9255 |
1. Xin W, Xiaohua N, Peilin C, Xin C, Yaqiong S, Qihan W. (2008) Primary function analysis of human mental retardation related gene CRBN.. Mol Biol Rep, 35 (2): (251-6). [PMID:17380424] |
2. Jo S, Lee KH, Song S, Jung YK, Park CS. (2005) Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channel in rat brain.. J Neurochem, 94 (5): (1212-24). [PMID:16045448] |
3. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H. (2010) Identification of a primary target of thalidomide teratogenicity.. Science, 327 (5971): (1345-50). [PMID:20223979] |
4. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M et al.. (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.. Leukemia, 26 (11): (2326-35). [PMID:22552008] |
5. Mazzoccoli L, Cadoso SH, Amarante GW, de Souza MV, Domingues R, Machado MA, de Almeida MV, Teixeira HC. (2012) Novel thalidomide analogues from diamines inhibit pro-inflammatory cytokine production and CD80 expression while enhancing IL-10.. Biomed Pharmacother, 66 (5): (323-9). [PMID:22770990] |
6. Eichner R, Heider M, Fernández-Sáiz V, van Bebber F, Garz AK, Lemeer S, Rudelius M, Targosz BS, Jacobs L, Knorn AM et al.. (2016) Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.. Nat Med, 22 (7): (735-43). [PMID:27294876] |
7. Quayle LA et al.. (2017) Anti-angiogenic drugs: direct anti-cancer agents with mitochondrial mechanisms of action.. Oncotarget, 8 (51): (88670-88688). [PMID:29179466] |
8. Rosa TLSA et al.. (2022) The Type I Interferon Pathway Is Upregulated in the Cutaneous Lesions and Blood of Multibacillary Leprosy Patients With Erythema Nodosum Leprosum.. Front Med (Lausanne), 9 (899998). [PMID:35733868] |